Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its kind — that activates two metabolic pathways simultaneously. This dual action leads to greater appetite suppression, improved blood sugar control, and more significant weight loss compared to GLP-1 medications alone.

In head-to-head clinical trials, tirzepatide demonstrated greater average weight loss than semaglutide — up to 22% of body weight vs. ~15–17% for semaglutide. Both are effective GLP-1-based therapies, but tirzepatide's dual mechanism may offer an advantage for patients who need stronger results.

Tirzepatide is a once-weekly subcutaneous injection. Your kit includes a pre-filled syringe, alcohol wipes, and step-by-step instructions. Your care team is available to guide you through your first injection and answer any questions.

In the SURMOUNT-1 trial, participants lost an average of 20.9% of their body weight over 72 weeks at the highest dose. Individual results vary based on adherence, starting weight, and lifestyle factors such as diet and exercise.

The most common side effects include nausea, diarrhea, decreased appetite, and constipation — primarily during the initial dose escalation period. These tend to be mild and resolve as your body adjusts. Your provider will titrate your dose gradually to minimize discomfort.

Yes — there are no long-term contracts or cancellation fees. You can pause or cancel your plan at any time directly from your member portal. Active orders already processed cannot be recalled, but future shipments will stop.